-transparent.png){kind=logo}
In a series of 23 patients bromocriptine increased the plasma estradiol-17 beta level from 44.0 +/- 9.5 (mean +/- SE) to 144.1 +/- 31.8 pg/ml after 3 - 5 weeks' treatment (p less than 0.01). In normoprolactinemic patients (N = 12) the level increased from 59.6 +/- 16.3 to 186.5 +/- 50.5 pg/ml (p less than 0.05), and in hyperprolactinemic patients (N = 11) the corresponding values were 27.0 +/- 6.2 and 97.8 +/- 34.6 pg/ml (p less than 0.05). Bromocriptine treatment did not significantly alter the FSH and LH levels. The results suggest that bromocriptine treatment induces endocrine recovery also in patients whose clinical findings give no indication of prolactin suppression.
M Seppälä, and
H A Unnérus, and
E Hirvonen, and
T Ranta
August 1981,
Horumon to rinsho. Clinical endocrinology,
M Seppälä, and
H A Unnérus, and
E Hirvonen, and
T Ranta
April 1985,
Lipids,
M Seppälä, and
H A Unnérus, and
E Hirvonen, and
T Ranta
October 1989,
Endocrinology,
M Seppälä, and
H A Unnérus, and
E Hirvonen, and
T Ranta
January 1983,
Acta Europaea fertilitatis,
M Seppälä, and
H A Unnérus, and
E Hirvonen, and
T Ranta
January 1984,
Breast cancer research and treatment,
M Seppälä, and
H A Unnérus, and
E Hirvonen, and
T Ranta
August 1974,
Obstetrics and gynecology,
M Seppälä, and
H A Unnérus, and
E Hirvonen, and
T Ranta
September 1983,
American journal of obstetrics and gynecology,
M Seppälä, and
H A Unnérus, and
E Hirvonen, and
T Ranta
June 1971,
The Journal of clinical endocrinology and metabolism,
M Seppälä, and
H A Unnérus, and
E Hirvonen, and
T Ranta
August 1983,
The Journal of experimental zoology,
M Seppälä, and
H A Unnérus, and
E Hirvonen, and
T Ranta
October 1970,
American journal of obstetrics and gynecology,
